表紙
市場調查報告書
商品編碼
1043351

腫瘤靶向免疫治療

Targeted Immunotherapy in Oncology

出版日期: | 出版商: Frost & Sullivan | 英文 106 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

在技術方面,非病毒基因傳遞和核酸傳遞具有很大的優勢,尤其是在免疫原性和致癌性等安全性方面。此外,沒有病毒載體使得監管途徑和生物製造過程更實惠,實際上價格更低,因為不需要額外的預防措施。

本報告探討了腫瘤學中的靶向免疫治療市場,並提供了市場概況、戰略要務、增長機會等。

目錄

第 1 章戰略勢在必行

  • 為什麼增長變得越來越困難?
  • 戰略要務:增長因素
  • 戰略要務
  • 三大戰略要務對靶向免疫治療的影響
  • 關於增長管道引擎 (TM)
  • 增長機會加速增長管道引擎 (TM)
  • 調查方法

第二章成長機會分析

  • 基因和細胞療法、基因編輯技術以及新的基因遞送平台越來越成功
  • 個性化靶向免疫治療框架
  • 突破性免疫治療技術平台
  • 一種有目的的免疫治療方法
  • 監管環境
  • 調查大綱
  • 調查範圍

第3章腫瘤靶向免疫治療的必要性

  • 用於癌症免疫治療的生物技術平台
  • 增長因素和加速因素
  • 挑戰與約束

第四章腫瘤靶向免疫治療技術評價

  • 靶向治療的分類
  • 增強靶向免疫治療的技術
  • 種系基因編輯工具和乾細胞重編程
  • 下一代靶向免疫治療的要求
  • 基因和細胞治療中的病毒和非病毒載體遞送
  • 基因治療中生物聚合物和生物加工的工藝機會
  • 創新生態系統和協作中心
  • 基因傳遞方面的主要夥伴關係和聯盟
  • 專注於靶向免疫治療中的病毒和非病毒基因遞送系統的公司
  • 促進靶向免疫治療成功的基因遞送系統中的新協同效應
  • 專注於基因編輯和乾細胞重編程技術的公司
  • 專注於化學技術的藥物化學和平台公司

第5章腫瘤靶向免疫治療的管線分析

  • 推動生物技術公司產品線和計劃的關鍵技術
  • 非病毒基因傳遞系統臨床驗證現狀
  • 競爭形勢
  • 最先進的處理管道儀表板:Inhibrx, Inc
  • 最先進的處理管道儀表板:BioNTech SE
  • 最先進的治療管道儀表板:Adapterimmune Therapeuticsllc
  • 最先進的處理管道儀表板:Asher Bio
  • 最先進的處理管道儀表板:Gritstone bio
  • 最先進的治療管道儀表板:Jounce Therapeutics, Inc

第六章利益相關者利用基因組工具進行研發

第 7 章特色公司

  • 罕見病基因治療,Ultragenyx Pharmaceutical,美國
  • AAV 基因傳遞技術,Spark Therapeutics (Roche),美國
  • 基因替代和基因敲除,Voyager Therapeutics,美國
  • AAV基因傳遞技術,AGTC,美國
  • LV 基因傳遞和 CART 細胞技術,BlueBird Bio,美國
  • DNA 納米粒子,Copernicus Therapeutics,美國

第八章融資與投資分析

  • 腫瘤靶向免疫治療的資金和投資評估
  • 靶向免疫治療平台的重大研發投資
  • 靶向免疫治療平台大宗交易
  • 靶向免疫治療平台的主要投資者
  • 靶向免疫治療平台的投資者動向
  • 政府資助靶向免疫治療平台
  • 靶向免疫治療平台主合約交易
  • 支持靶向免疫治療平台上的主要交易
  • 靶向免疫基因治療中的風險投資融資評估
  • 靶向免疫基因治療中的風險投資融資交易

第九章主要利益相關方專利組合分析

  • 衝突信息,Beam Therapeutics
  • 競爭信息,BlueBird Bio
  • 衝突信息,Generation Bio

第 10 章增長機會領域

  • 增長機會 1:罕見遺傳病的基因傳遞和核酸傳遞
  • 增長機遇 2:精準免疫治療的創新生物技術平台
  • 增長機會 3:模塊化分散式製造,可負擔得起的靶向基因免疫療法
  • 靶向免疫治療的風險管理最佳實踐

第 11 章後續步驟

目錄
Product Code: D9F5

Developments in Biotechnology Platforms Leading to Increasing Immuno-oncology Applications

This research service investigates technologies that propel the development of new targeted immunotherapies, particularly those that deliver therapeutic DNA and proteins. The top 3 growth opportunities focus on enhanced gene delivery systems for greater precision, the support of such systems through novel biotech platforms, and the affordability of precision medicine/targeted immunotherapies through modular, decentralized manufacturing systems.

Regarding technology, nonviral gene delivery and nucleic acid delivery offer significant advantages in terms of safety, particularly from immunogenicity and carcinogenicity. Not using viral vectors also makes the regulatory pathway and the biomanufacturing process more affordable because no additional precautions are needed; this, in fact, makes the price tag lower.

The study touches on the advantages and limitations of viral and nonviral gene delivery systems for targeted immunotherapies. Safety of administration without immunogenicity remains as the most relevant advantage. Liposomes have no replication risk and are less immunogenic than viruses.

Other benefits are:

  • a practically unlimited transgene size;
  • the possibility of repeated administration;
  • a cost-affordable model; and
  • an easy manner to produce them in large amounts.

The plurality of gene delivery systems is broadly benchmarked in terms of transfection efficiency, precision in cancer immunotherapy, and capability to pass the membrane barrier.

As for remarkable innovation in biotech platforms, the research highlights gene addition as a novel approach that uses a delivery system to insert new genes directly into cells.

The addition of a functional gene can take place either outside (ex vivo) or inside (in vivo) the body and can be used in cancer immunotherapy through CAR T-cell technology.

Gene delivery strategies are based on a comprehensive suite of clinically validated technologies, including electroporation, liposomes, nanoparticles, and nonviral and viral delivery modalities. Electroporation is best suited for efficient delivery to blood cells and immune cells ex vivo. Lipid nanoparticles (LNP) are better indicated for in vivo delivery to the liver and potentially other organs. Adenoassociated vectors are typically used for in vivo delivery to the eye and central nervous system (CNS).

As for optimal manufacturing process, closed-ended DNA (ceDNA) vectors exhibit a linear and continuous structure, which can be used for insertion of a transgene into a gene safe harbor (GSH) in the genome. For gene delivery, cell-targeted lipid nanoparticle (ctLNP) designed to avoid activation of the immune system upon initial dose can be used, while capsid-free approaches can be utilized to facilitate manufacturing.

This research profiles a remarkable number of companies succeeding in the targeted immunotherapy space. A competitive analysis of the top three innovators, based on their IP activity and patent innovation focus, is included. Funding and investment, including leading deals and investors focused on the technologies empowering targeted immunotherapies, are also covered.

Key Points Discussed:

  • 1. Top innovations in biotechnology platforms focused on targeted immunotherapies
  • 2. Emerging technologies in gene and nucleic acids direct delivery systems
  • 3. Outstanding companies succeeding the targeted immunotherapy space
  • 4. Industry landscape and patent filing trends in the industry
  • 5. Major deals and investors focused on developing novel technologies for targeted immunotherapies
  • 6. Growth opportunities in the targeted immunotherapy area
  • 7. Best practices for risk management during the development of new technologies that enhance targeted immunotherapies

Table of Contents

1.0 Strategic Imperatives

  • 1.1 Why Is It Increasingly Difficult to Grow?The Strategic Imperative 8™: Factors Creating Pressure on Growth
  • 1.2 The Strategic Imperative 8™
  • 1.3 The Impact of the Top Three Strategic Imperatives on Targeted Immunotherapies
  • 1.4 About The Growth Pipeline Engine™
  • 1.5 Growth Opportunities Fuel the Growth Pipeline Engine™
  • 1.6 Research Methodology

2.0 Growth Opportunity Analysis

  • 2.1 Rising Success of Gene and Cell Therapies, Gene Editing Techniques, and Novel Gene Delivery Platforms
  • 2.2 Framework for Personalized Targeted Immunotherapy
  • 2.3 Groundbreaking Immunotherapy Technology Platforms
  • 2.4 Fit-for-Purpose Immunotherapy Approaches
  • 2.5 Regulatory Environment
  • 2.6 Research Context
  • 2.7 Research Scope

3.0 The Need for Targeted Immunotherapy in Oncology

  • 3.1 Biotech Platforms for Cancer Immunotherapy
  • 3.2 Drivers and Accelerators
  • 3.3 Challenges and Restraints

4.0 Technology Assessment of Targeted Immunotherapies in Oncology

  • 4.1 Classification of Targeted Therapies
  • 4.2 Technologies Empowering Targeted Immunotherapies
  • 4.2 Technologies Empowering Targeted Immunotherapies (continued)
  • 4.3 Germline Gene Editing Tools and Stem Cell Reprogramming
  • 4.4 Next-Generation Targeted Immunotherapy Requirements
  • 4.5 Viral and Nonviral Vector Delivery in Gene and Cell Therapies
  • 4.6 Process Opportunity Plays for Biopolymers & Bioprocessing in Gene Therapy
  • 4.7 Innovation Ecosystem and Collaboration Hubs
  • 4.8 Key Partnerships and Alliances in Gene Delivery
  • 4.9 Companies Focused on Viral and Nonviral Gene Delivery Systems in Targeted Immunotherapy
  • 4.10 Novel Synergies in Gene Delivery Systems Driving Targeted Immunotherapy Success
  • 4.11 Companies Focused on Gene Editing and Stem Cell Reprogramming Technologies
  • 4.12 Companies Focused on Medicinal Chemistry and Platform Chemistry Technologies

5.0 Pipeline Analysis of Targeted Immunotherapies in Oncology

  • 5.1 Principal Technologies Propelling Biotech Company Pipelines and Programs
  • 5.2 Clinical Validation Status of Nonviral Gene Delivery Systems
  • 5.3 Competitive Landscape
  • 5.4 State-of-the-Art Therapeutics Pipeline Dashboard: Inhibrx, Inc.
  • 5.5 State-of-the-Art Therapeutics Pipeline Dashboard: BioNTech SE
  • 5.6 State-of-the-Art Therapeutics Pipeline Dashboard: Adaptimmune Therapeutics llc.
  • 5.7 State-of-the-Art Therapeutics Pipeline Dashboard: Asher Bio
  • 5.8 State-of-the-Art Therapeutics Pipeline Dashboard: Gritstone bio
  • 5.9 State-of-the-Art Therapeutics Pipeline Dashboard: Jounce Therapeutics, Inc.

6.0 Stakeholders Leveraging Genome Tools for R&D

  • 6.1 In vivo Gene Transfer, Homology Medicines, US
  • 6.2 Next-Generation AAV Capsids, Abeona Therapeutics, US
  • 6.3 CRISPR Gene Editing, Editas Medicine, US
  • 6.4 AAV, Zinc Finger Nucleases, Sangamo Therapeutics, US
  • 6.5 Electroporation, Nonviral (LNP), Viral (AAV), Beam Therapeutics, US
  • 6.6 Customized AAV Vectors, 4D Molecular Therapeutics, US
  • 6.7 T-Cell Immunotherapy-Microfluidic Vortex Shedding, Indee Labs, US
  • 6.8 Precise Gene Editing Technology, Poseida Therapeutics, US
  • 6.9 Lentiviral Gene Delivery, Avrobio, US

7.0 Companies to Action

  • 7.1 Gene Therapy for Rare Diseases, Ultragenyx Pharmaceutical, US
  • 7.2 AAV Gene Delivery Technology, Spark Therapeutics (Roche), US
  • 7.3 Gene Replacement and Gene Knockdown, Voyager Therapeutics, US
  • 7.4 AAV Gene Delivery Technology, AGTC, US
  • 7.5 LV Gene Delivery and CAR T-cell Technology, BlueBird Bio, US
  • 7.6 DNA Nanoparticles, Copernicus Therapeutics, US

8.0 Funding and Investment Analysis

  • 8.1 Funding and Investment Assessment in Targeted Immunotherapy for Oncology
  • 8.2 Leading R&D Investments in Targeted Immunotherapy Platforms
  • 8.3 Principal Deals in Targeted Immunotherapy Platforms
  • 8.3 Principal Deals in Targeted Immunotherapy Platforms (continued)
  • 8.3 Principal Deals in Targeted Immunotherapy Platforms (continued)
  • 8.3 Principal Deals in Targeted Immunotherapy Platforms (continued)
  • 8.3 Principal Deals in Targeted Immunotherapy Platforms (continued)
  • 8.3 Principal Deals in Targeted Immunotherapy Platforms (continued)
  • 8.4 Leading Investors in Targeted Immunotherapy Platforms
  • 8.5 Investor Movements in Targeted Immunotherapy Platforms
  • 8.5 Investor Movements in Targeted Immunotherapy Platforms (continued)
  • 8.5 Investor Movements in Targeted Immunotherapy Platforms (continued)
  • 8.5 Investor Movements in Targeted Immunotherapy Platforms (continued)
  • 8.6 Government Funding in Targeted Immunotherapy Platforms
  • 8.6 Government Funding in Targeted Immunotherapy Platforms (continued)
  • 8.7 Prime Contract Transactions in Targeted Immunotherapy Platforms
  • 8.8 Assistance Prime Transactions in Targeted Immunotherapy Platforms
  • 8.9 Venture Capital Funding Assessment in Targeted Immunogene Therapy
  • 8.10 Venture Capital Funding Deals in Targeted Immunogene Therapy

9.0 Patent Portfolio Analysis of Key Stakeholders

  • 9.1 Competitive Intelligence, Beam Therapeutics
  • 9.1 Competitive Intelligence, Beam Therapeutics (continued)
  • 9.2 Competitive Intelligence, BlueBird Bio
  • 9.3 Competitive Intelligence, Generation Bio

10.0 Growth Opportunity Universe

  • 10.1 Growth Opportunity 1: Gene Delivery and Nucleic Acid Delivery for Rare and Genetic Diseases
  • 10.1 Growth Opportunity 1 Explained: Gene Delivery and Nucleic Acid Delivery for Rare and Genetic Diseases (continued)
  • 10.2 Growth Opportunity 2: Innovative Biotech Platforms for Precision Immunotherapy
  • 10.2 Growth Opportunity 2: Innovative Biotech Platforms for Precision Immunotherapy (continued)
  • 10.2 Growth Opportunity 2: Innovative Biotech Platforms for Precision Immunotherapy (continued)
  • 10.3 Growth Opportunity 3: Modular, Decentralized Manufacturing for Affordable Targeted Gene Immunotherapy
  • 10.3 Growth Opportunity 3 Explained: Modular, Decentralized Manufacturing for Affordable Targeted Gene Immunotherapy (continued)
  • 10.3 Growth Opportunity 3: Modular, Decentralized Manufacturing for Affordable Targeted Gene Immunotherapy (continued)
  • 10.4 Best Practices for Risk Management in Targeted Immunotherapy

11.0 Next Steps

  • 11.1 Your Next Steps
  • 11.2 Why Frost, Why Now?
  • Legal Disclaimer